| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6677 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 5026 | 2018 |
| Pembrolizumab as second-line therapy for advanced urothelial carcinoma J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ... New England Journal of Medicine 376 (11), 1015-1026, 2017 | 3748 | 2017 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2748 | 2019 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1849 | 2021 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1552 | 2020 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 1104 | 2019 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The lancet oncology 20 (10), 1370-1385, 2019 | 846 | 2019 |
| Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ... New England Journal of Medicine 385 (8), 683-694, 2021 | 827 | 2021 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 615 | 2020 |
| Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial R Pettengell, H Gurney, JA Radford, DP Deakin, R James, PM Wilkinson, ... | 561 | 1992 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 519 | 2020 |
| Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ... Annals of Oncology 31 (8), 1030-1039, 2020 | 499 | 2020 |
| Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of> 2 years of follow-up Y Fradet, J Bellmunt, DJ Vaughn, JL Lee, L Fong, NJ Vogelzang, ... Annals of Oncology 30 (6), 970-976, 2019 | 498 | 2019 |
| Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. H Gurney Journal of Clinical Oncology 14 (9), 2590-2611, 1996 | 455 | 1996 |
| Electronic cigarettes and health outcomes: umbrella and systematic review of the global evidence E Banks, A Yazidjoglou, S Brown, M Nguyen, M Martin, K Beckwith, ... Medical Journal of Australia 218 (6), 267-275, 2023 | 417* | 2023 |
| How to calculate the dose of chemotherapy H Gurney British journal of cancer 86 (8), 1297-1302, 2002 | 377 | 2002 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 355 | 2023 |
| Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, ... Cancer 126 (18), 4156-4167, 2020 | 348 | 2020 |
| Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label … RJ Motzer, T Powles, M Burotto, B Escudier, MT Bourlon, AY Shah, ... The Lancet Oncology 23 (7), 888-898, 2022 | 339 | 2022 |
Martin StocklerNHMRC Clinical Trials Centre, University of SydneyVerified email at sydney.edu.au
